Screener
Collegium Pharmaceutical, Inc. COLL Nucynta Products — Cost, Amortization
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSoldAmortization.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Jornay PM | $20,957 | $20,957 | $41,914 | $41,914 |
| Belbuca | 18,849 | 18,849 | 37,698 | 37,697 |
| Nucynta Products | 13,846 | 13,846 | 27,692 | 27,692 |
| Azstarys | 7,480 | — | 7,480 | — |
| Symproic | 1,821 | 1,821 | 3,642 | 3,643 |
| Total amortization expense | $62,953 | $55,473 | $118,426 | $110,946 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s nucynta products — cost, amortization?
- Collegium Pharmaceutical, Inc. (COLL) reported nucynta products — cost, amortization of $13.85M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s nucynta products — cost, amortization changed year-over-year?
- Collegium Pharmaceutical, Inc.'s nucynta products — cost, amortization decreased by 0.0% year-over-year, from $13.85M to $13.85M.
- What does nucynta products — cost, amortization mean?
- The periodic non-cash expense recognized to allocate the cost of Nucynta-related intangible assets over their estimated useful lives. Monitoring this expense helps investors understand the impact of acquisition-related accounting on reported segment earnings.
Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta products — cost, amortization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude